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oAbstract
Diffuse Large B-Cell Lymphoma (DLBCL) is a clinically and biologically heterogeneous disease. The revised Classification of
Lymphoproliferative diseases published in 2016 (WHO, 2016) refined the previous DLBLC subtypes and identified four categories:
DLBCL not otherwise specified (NOS), other lymphomas of large B cells, high grade B-cell lymphoma, and B-cell lymphoma
unclassifiable. High grade B-cell lymphomas include the entities carrying MYC, BCL2 and/or BCL6 translocations or cases with
blastoid morphology without DH translocations. This classification also acknowledges the cell of origin (COO) classification, that has
only a limited impact on the choice of frontline treatment for DLBCL, as most patients still receive R-CHOP chemoimmunotherapy.
Attempts to improve the outcomes of specific subgroups, especially COO groups, have so far had limited success. Newer analyses
have further subdivided DLBCL into genomically distinct subsets, not yet incorporated in the WHO classification, which may facilitate
targeted approaches to therapy. In this review, we discuss the subgroups that are recognized by theWHO 2016 classification, review
the newer genomic data, and speculate on how this could alter the treatment landscape of DLBCL in the future.We also discuss novel
approaches to salvage therapy in the broad context of the heterogeneity of DLBCL.Introduction has only a limited impact on the choice of frontline treatment forDiffuse Large B-Cell Lymphoma (DLBCL) is a clinically and
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1DLBCL, as most patients still receive R-CHOP chemoimmuno-
therapy. Attempts to improve the outcomes of specific subgroups,
especially COO groups, have so far had limited success. However,
newer analyses have further subdivided DLBCL into genomically
distinct subsets, not yet incorporated in the WHO classification,
which may facilitate targeted approaches to therapy. In this review,
we discuss the subgroups that are recognized by the WHO 2016
classification, review the newer genomic data, and speculate on how
this could alter the treatment landscape of DLBCL in the future.We
also discuss novel approaches to salvage therapy in the broad
context of the heterogeneity of DLBCL.Cell of origin in DLBCL NOS
In year 2000, Alizadeh et al reported that DLBCL patients
analyzed using gene expression profiling (GEP) could be divided
in subgroups according to the cell of origin (COO).2 They
identified three subgroups according to diversity in gene
expression: the germinal Centre B-cell-like (GCB) in 40% to
50%of patients, the Activated B-Cell-like (ABC) in 50% to 60%
of patients and an unclassifiable group. The distinct subgroups
present gene expression patterns indicative of different stages of
B-cell differentiation, and patients with GCB lymphoma has a
better survival in comparison with ABC patients. Subsequent
studies confirmed the different biological characteristics and
clinical behavior according to the COO classification.3,4 The
ABC subtype is driven by frequent mutations in the B cell
receptor and NFKB pathways, as well as in CARD11, CD79a/
CD79b and MYD88. MYD88 L265P mutation is present in
29% of ABC patients and is associated with extranodal disease
Table 1
DLBCL Classification According to WHO1
Diffuse large B-cell lymphoma, NOS
Morphologic variants
Centroblastic
Immunoblastic
Anaplastic
Other rare variants
Molecular subtypes
Germinal centre B-cell subtype
Activated B-cell subtype
Other lymphomas of large B cells
High-grade B-cell lymphoma
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
High-grade B-cell lymphoma, NOS
B-cell lymphoma unclassifiable
B-cell lymphoma unclassifiable, with features intermediate between diffuse large
B-cell lymphoma and classic Hodgkin lymphoma
A. Chiappella et al. Are We Ready to Treat Diffuse Large B-Cell and High-Grade(breast, testis, stomach, central nervous system) and poor
outcome.5 In contrast, the GCB subtype is characterized by
frequent mutations in phosphoinositide 3-kinase (PI3K) and
apoptotic pathways.
Since the GEP methods are not applicable in the routine
practice, numerous immune histochemical (IHC) algorithms have
been developed as surrogates of GEP to assign the COO. The
Hans algorithm using IHC for CD10, BCL6 and MUM-1/IRF4
with a cut off of 30% of reactivity is the most used and divides
DLBCL into GCB and non-GCB. The concordance of the Hans
algorithm with GEP is approximately 76%,6 which limits its use
as a tool for clinical trial or personalized treatment approaches.
More recently, a newGEP technique was applied: theNanoString
Research Use Only Lymphoma Subtyping (NanoStringTechnol-
ogies, Inc., Seattle, WA) based on the analysis of 20 genes on
formalin-fixed paraffin embedded samples. The Lymph2Cx assay
was tested and reported a concordance of >95% with standard
GEP, with an advantage in term of turnaround time, feasibility
(fresh biopsies not required) and costs.7 This new technology was
used for the analysis of large cohorts of patients treated with R-
CHOP regimen in large prospective trials, but has yielded
discordant results. The British Columbia Cancer Agency showed
better prognosis for patients with GCB profile8 whereas the
German High-grade Non Hodgkin Study group analyzed
samples of two large randomized trials (RICOVER-60 and R-
MegaCHOEP) and failed to identify any difference between GCB
and ABC subtypes.9 These controversial results should not be
clearly justified, but they may be due to a selection of low-risk
patients in the subgroup of patients evaluated in the German
studies; it should be underlined that in the more intensive
schemes, R-CHOP14 or R-Mega-CHOEP, the role of COO
seems to be less important that in the standard R-CHOP21 series.
More recently, the GOYA study analyzed prospectively survivals
of 1418 patients treated with R-CHOP or Obinutuzumab-CHOP
by COO subtype. The assignment to COO classes (GCB, ABC
and unclassified) was performed by Nanostring and showed a
significantly higher 3-year progression-free survival (PFS) for
GCB subtype (75% vs 59% and 63% in other subgroups).10 The
revised version of the WHO classification in 2016 integrated the
COO in the B lymphoma classification and recommends the
assessment of cell of origin in all cases of DLBCL at least
according to the Hans algorithm, despite the caveat above. While
several agents (bortezomib, ibrutinib, lenalidomide) have shown2increased activity in ABC-subtype DLBCL, their incorporation in
frontline therapy has not yet shown superiority.11–14 This
suggests that the COO may not capture enough of the molecular
heterogeneity of DLBCL to allow targeted therapy.Double hit and triple hit lymphomas
Double and triple hit lymphomas are new entities in the 2016
WHO classification and are included in the High Grade B-cell
Lymphoma category. These tumors harbor a rearrangement
of the MYC gene and of the BCL2and/or BCL6 gene. Double
hit lymphomas (DHL) comprise approximately 10% of all
DLBCL, with MYC/BCL2 being the more frequent subtype
(65% of DHL cases), followed by MYC/BCL2/BCL6 triple hit
(THL) lymphomas (20% of cases) and by MYC/BCL6 DHL
(10% of cases).15–17 Most DHLs are of the GCB subtype.
Double and triple hit lymphomas are very aggressive, present
with advanced stage disease frequently involving the bone
marrow and extranodal sites such as central nervous system and
have a very poor prognosis. Treatment of these patients with
standard chemotherapy R-CHOP is associated with dismal
outcome with a median overall survival of 12 months from
diagnosis. Many attempts to ameliorate the prognosis of these
patients have been investigated. While no molecularly targeted
approach has yet shown success, several studies have suggested
that intensified chemotherapy regimens can improve the
outcomes of these patients.18,19 The very poor prognosis of
patients with relapsed/refractory DHL/THL makes imperative
the development of effective (and ideally molecularly targeted)
frontline regimens. A better understanding of the fundamental
biology and therapeutic vulnerabilities of these tumors is a
major unmet clinical need at present.Double expressor lymphoma
MYC and BCL2 represent two oncogenes implicated in
proliferation and apoptosis and are key regulators of DLBCL
pathogenesis. As noted above, concurrent chromosomal trans-
locations are associated with aggressive and refractory clinical
behavior in DLBCL. However, other mechanisms can result in
overexpression of the proteins on the tumor cell surface,
independently of translocation events. The concomitant double
expression of MYC and BCL2 is present in 20% to 30% of
DLBCL; the group of DLBCL with these characteristics is termed
double expressor lymphomas (DEL), but it is not a different
biological entity. This phenotype is more frequent in the ABC
subgroup. The cut off for positivity is still matter of debate,
however, expression of BCL2 more or equal to 50% and MYC
expression more or equal to 40% as originally reported is
considered adequate.1 DELs have been associated with an
inferior prognosis under RCHOP treatment.15,20–22 However,
and despite the recognition of the adverse associated prognosis,
the biology of DELs is still unclear; indeed, in the updated WHO
this entity has not been assigned to a specific category and is
grouped within DLBCL NOS. To date no specific treatment has
been shown to mitigate this adverse prognosis. Of note, the single
expression of MYC is present in 25% to 30% of lymphoma,
irrespective of COO, and does not represent an adverse
prognostic factor in patients treated with R-CHOP.23 In contrast,
BCL2 overexpression is highly correlated with ABC subgroup,
and in some series has been associated with inferior PFS,
independently from international prognostic index (IPI) and
COO.24
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In DLBCL, gene expression profiling was first used to identify
subgroups according to COO. In 2018 Schmitz et al25 published
a multiplatform genomic analysis of 574 fresh frozen samples of
DLBCL and identified 4 genetic subtypes within the GCB and
ABC groups; because the genetic composition of unclassified
DLBCL is unknown, they were enriched for mutations. The first
subtype is characterized by MYD88 and CD79B mutations
(MCD) and is more frequent among ABC lymphomas; the second
subtype is characterized by BCL6 fusions and NOTCH2
mutations (BN2) and is represented in similar proportions
among ABC and GCB; the third is characterized by NOTCH1
mutations (N1), and is present more frequently among ABC the
last subtype is characterized by EZH2 mutations and BCL2
translocations (EZB), and is present more frequently in GCB.
Overall, authors estimated that, on the basis of the gene-
expression predictor classifications of MCD, BN2, N1, and EZB
cases, these genetic subtypes would comprise 46.6% of cases.
Furthermore, an analysis of clinical outcome was performed on
among 117 patients treated with R-CHOP whose tumor was
classified into one of the genetic subtypes. The 5-year overall
survival (OS) differed significantly between the groups and was
26%, 36%, 65%, and 68% for MCD, N1, BN2, and EZB
respectively.
In another study, Chapuy et al26 performed whole exome
sequencing of 304 primary DLBCL to detect low frequency
mutations, somatic copy number alterations and structural
variants. They identified five distinct DLBCL subsets: cluster 5
lymphomas had frequent gains in chromosome 18q with
increased expression of BCL2 and MALT1, as well as mutations
in CD79 andMYD88; those tumors are often in the ABC group;
cluster 1 exhibited BCL6 single variants and mutations of
NOTCH2 signaling and are also most often of the ABC type;
cluster 3 is a poor risk GCB group with BCL2 translocations and
alterations of PTEN; cluster 4 is a favorable risk GCB group with
alterations in BCR/PI3K, JAK/STAT, and BRAF pathway; finally,
cluster 2 is a COO-independent group with frequent biallelic
inactivation of TP53, loss of CDKN2A and genomic instability.
Interestingly, the genetic subgroups identified independently by
the 2 aforementioned studies are overlapping, with the cluster 5
corresponding to MCD, cluster 1 to BN2 and cluster 3 to EZB
subgroups. These new molecular classifications likely offer more
molecular homogeneity than the original COO classification, and
indeed allow the splitting of GCB and ABC groups into
biologically distinct subgroups. This should help in targeting
specific vulnerabilities and allowing a more personalized
treatment approach in patients with DLBCL. Such studies are
now beginning, but ultimately the value of these classifications
will need to be demonstrated in prospective trials.First-line treatment of advanced stage disease
The standard treatment of advanced stage DLBCL is the
monoclonal antibody anti-CD20 rituximab in combination to
cyclophosphamide-doxorubicin-vincristine-prednisone (R-
CHOP).27 Despite the high rate of complete response (76%) at
the end of the treatment and an impressive long-term outcome,
with 10-year progression-free survival (PFS) of 37% and overall
survival (OS) of 44%, roughly the 40% of the patients
experienced relapse or progression.28
In young patients with advancedDLBCL at good prognosis (no
risk factors or one risk factor according to age-adjusted3International Prognostic Index, IPI, at stage II-IV disease, or
stage I disease with bulk), the standard treatment was represented
by six courses of R-CHOP.29 The updated MInT data, at a 6-
years follow-up, suggested a central role of radiotherapy on bulky
disease in less-favorable group of young patients.30 To investigate
a potential survival benefit of a dose-intensive regimen compared
to chemoimmunotherapy in young patients at low-intermediate
risk (age-adjusted IPI 1), the French group conducted a
randomized trial comparing dose-intensive rituximab, doxoru-
bicin, cyclophosphamide, vindesine, bleomycin, and prednisone
(R-ACVBP) versus standard R-CHOP. This study suggested that
more aggressive treatment may improve outcome in young
DLBCL patients at low-intermediate IPI risk, with raised but
manageable toxicities.31 Indeed, in this study R-CHOP21
regimen was given without radiotherapy and the results obtained
with R-ACVBP were superimposable to those obtained in the
MInT trial with R-CHOP plus radiotherapy.
In order to ameliorate the prognosis of advanced DLBCL at
high risk, 2 large randomized trials were conducted, to compare
the standard R-CHOP every 21 days with a dose-dense R-CHOP
performed every 14 days; the results were superimposable into
the 2 arms.32,33 In young patients with DLBCL at poor prognosis
according to international prognostic index, several options have
been investigated to improve outcomes, including the introduc-
tion of consolidation with high-dose chemotherapy plus autolo-
gous stem-cell transplantation (ASCT) as part of the first-line
treatment. Four randomized trials were conducted, comparing a
full course of R-CHOP (or intensified R-CHOP) with or without
intensification with high-dose chemotherapy followed by ASCT;
the intensification was able to reduce failures in 2 studies, but no
advantage in overall survival was shown. In the SWOG-9704
trial, 397 patients were treated with 5 courses of CHOP21 or R-
CHOP21, and 253 responsive patients were randomized to
receive 3more cycles of CHOP21 or 1 cycle of CHOP21 followed
by ASCT conditioned by total body irradiation or carmustine
containing regimen. The study showed an improvement in PFS in
transplantation group compared with no transplantation, but no
benefit in OS was observed.34 A benefit in terms of Failure Free
Survival (FFS) was reported by the phase 3 randomized trial FIL-
DLCL04; in the Italian trial, 399 young patients with DLBCL at
high-risk were randomized to receive a full course of chemo-
immunotherapy at 2 different level of intensification (R-
CHOP14/R-MegaCHOP14) or a short course of the same
scheme followed by intensification with high-dose cytarabine,
mitoxantrone and dexamethasone, followed by ASCT condi-
tioned by BEAM (carmustine, cytarabine, etoposide, melphalan)
regimen. An advantage in FFS at 2-year of 71% (95%, CI 64–77)
in the transplantation group vs 62% (95%, CI 55–68) in the non-
transplant group, hazard ratio (HR) 0.65 (95%, CI 0.47–0.91)
was observed, but this difference did not translate in an
advantage of OS.35 No differences in OS nor in PFS between
transplant and no transplant were reported in other 2 studies: the
German DSHNHL 2002-1 trial, comparing R-CHOP14 plus
etoposide (R-CHOEP14) and the more toxic intensified R-
MegaCHOEP14 followed by ASCT, and the Italian GITIL trial,
comparing 8 cycles of R-CHOP14 with an high-dose sequential
chemotherapy program.36,37
An alternative and intensive infusional regimen is the dose-
adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclo-
phosphamide, doxorubicin, and rituximab), tested on untreated
DLBCL in a phase II trial by The Cancer and Leukemia Group B
(CALGB), obtaining a 4-year PFS of 81%.38 To demonstrate the
superiority of DA-EPOCH-R compared to R-CHOP, the
A. Chiappella et al. Are We Ready to Treat Diffuse Large B-Cell and High-GradeCALGB/Alliance conducted a phase III randomized study in 524
DLBCL patients. Authors concluded that, despite increase
toxicity and complexity in DA-EPOCH-R treated patients, there
was no improvement in PFS, OS, or response rate compared to
standard R-CHOP. In a post hoc comparison of PFS by arm in
subgroups of age, lactate dehydrogenase level, Eastern Coopera-
tive Oncology Group performance status, extranodal disease,
stage and IPI risk group, patients with intermediate-high IPI risk
treated with DA-EPOCH-R seemed to have a benefit in term of
PFS compared to those treated with R-CHOP, but it was an
unplanned and not powered analysis.39
An unmet clinical need in the treatment of DLBCL was
represented by the risk of relapse in the central nervous system
(CNS), an uncommon but devastating event, that occurred in up
to 10% of advanced DLBCL at high-risk. The addition of
rituximab to standard chemotherapy has contributed to a
reduction in both systemic and CNS relapse, but it was not
enough.40,41 The best strategy to prevent CNS dissemination was
not yet established; intrathecal injections of methotrexate seems
to be a suboptimal method, whereas intravenous high-dose
methotrexate has been shown to be associated with efficient
disease control.42 Some data reported a reduced incidence in CNS
recurrence in combined chemoimmunotherapy with biological
drugs (lenalidomide, ibrutinib).43,44First-line treatment of double expressors,
double or triple hit lymphomas
The outcome of DEL, DHL, and THL is unsatisfactory with
standard R-CHOP. Nowadays, the single MYC rearrangement
or the overexpression of Bcl2 and MYC, are not yet considered
validated risk factors, and R-CHOP still remain the standard
therapeutic option. Nevertheless, several studies reported the
advantage of intensified treatment in this setting. DA-EPOCH-R
was tested in 53 patients at high risk and with single hit (MYC) or
double hit, obtaining durable remission, with 4-year EFS of 71%
(95% CI 56,5–81,4) and 4-year OS of 76,7% (95% CI 62,6–
86,1) for all patients.45
In a recent Italian study, 114 consecutive patients with double
expressors DLBCLwere identified and treated with DA-EPOCH-
R in 51 and R-CHOP in 63 patients; in this series of patients, the
treatment with DA-EPOCH-R was associated with a significant
improvement of PFS and OS in young patients and an advantage
in term of PFS in favor of DA-EPOCH-R was seen in all patients
with genetic abnormalities (single translocations, atypical double
hit and double or triple hit). The data are encouraging, but
retrospective and thus need to validated in a prospective trial.46
Due to the rarity of the disease, there are no prospective trials in
the setting of DHL or THL that represents a critical unmet clinical
need. Due to the high proliferation and the risk of central nervous
system (CNS) dissemination, R-CHOP is not adequate, with a
median PFS of 7.3 months, and more intensive treatments, such
as schemes used in Burkitt lymphomas containing high dose
methotrexate and cytarabine are frequently used. Petrich et al19
published a pooled retrospective analysis in which patients with
DHL were treated with R-CHOP or intensive induction therapy,
which included the dose-adjusted R-EPOCH regimen, Hyper-
CVAD/MA fractionated cyclophosphamide, vincristine, doxoru-
bicin, dexamethasone, alternating with methotrexate and
cytarabine, or CODOX-M/IVAC. Response rates in this non-
randomized retrospective study were highest for dose-adjusted
R-EPOCH. Intensive induction was associated with improved4progression-free survival and improved overall survival on
multivariable analysis.
The so called “Magrath scheme”, with alternate R-CODOX-
M/R-IVAC (rituximab-cyclophosphamide, vincristine, doxoru-
bicin, methotrexate, ifosfamide, etoposide, cytarabine) is an
aggressive regimen developed for Burkitt lymphoma used in
aggressive lymphomas. Twenty-five patients affected by DHL
were treated at the British Columbia Cancer Agency (BCCA)with
R-Magrath and achieved a CR rate of 36%, with a 2-year PFS of
47% (95% CI, 30- 64%) and a 2-year OS of 61% (95% CI, 46–
76%).47
The MD Anderson Cancer Center reported a retrospective
series of 129 patients; CNS involvement occurred in 13% of
patients. The 2-year EFS in patients who received R-CHOP, R-
EPOCH, and R-HyperCVAD/MA were 25%, 67%, and 32%,
respectively.18
In patients obtaining a complete response after induction, a
consolidation with high-dose chemotherapy and ASCT, not
seems to determine a better PFS and OS, but no prospective or
randomized data are available.48 Considering that themajority of
DHL patients have more than 65 years at diagnosis and thus are
not eligible for intensified treatments, DA-EPOCH-R scheme
should be a feasible therapeutic option in the elderly.Salvage treatment in patients eligible to high
dose treatment
Since the PARMA trial, in the pre-rituximab era, a high-dose
cisplatin and cytarabine-containing regimen (DHAP) followed by
high-dose chemotherapy and autologous stem cell transplanta-
tion was considered the standard treatment in relapsed/refractory
DLBCL patients, with a 5-years OS of 53%.49 In patients eligible
to intensive treatment, in relapsed and refractory setting, the high
dose chemotherapy followed by ASCT is still the standard of care
in the rituximab-era.42 The addition of rituximab to second-line
chemotherapy followed by ASCT significantly improved PFS in
patients not exposed to rituximab as part of their first-line
treatment. In the CORAL trial, 396 patients with DLBCL
relapsed/refractory after CHOP with/without rituximab, were
randomized to receive rituximab, ifosfamide, carboplatin, and
etoposide (R-ICE) or rituximab, dexamethasone, high-dose
cytarabine, and cisplatin (R-DHAP); responsive patients were
given BEAM plus ASCT.50 In the CORAL trial, 48% of the
patients did not underwent transplantation, the majority due to
lack of response to induction; this finding represent the most
important limitation of the study. However, this study was
helpful to identify prognostic parameters at relapse correlated to
lower 3-years PFS and OS (P< .001): prior rituximab treatment,
early relapse (within 12months) and a high score age-adjusted IPI
score. In particular, early relapse and prior rituximab exposure,
identified a group at dismal prognosis, with 3-year PFS of 23%.
However, even in this unfavorable population, patients who
underwent ASCT showed a better outcome compared to those
not underwent ASCT (3-year PFS of 39% vs 14%, P < 0.001).
Among the 396 patients included into the trial, 249 patients had
histologic material available, and were studied for COO
according to Hans profile. Based on COO assessed by
immunohistochemistry, patients with non-GCB have a worse
prognosis compared to GCB irrespective to R-DHAP or R-ICE
chemotherapy; furthermore, GCB-like patients have an improved
outcome when treated with R-DHAP compared with R-ICE in
the CORAL randomized trial.51
(2019) 3:5 www.hemaspherejournal.comIn high-grade B-cell lymphoma, patients that experienced
relapse and refractory disease after front line treatment had a
dismal prognosis irrespective to the second line approach, and no
standard therapeutic approach has been defined.52
Herrera et al, retrospectively studied the impact of DEL or DH
status in a multicenter cohort of 78 patients (40% DLBCL, 47%
DEL, 13% DHL) relapsed or refractory, who underwent
allogeneic stem cell transplantation (alloSCT). There were no
significant differences in 4-year PFS or OS between patients with
DEL compared with patients without DEL (PFS 30% versus
39%, P = 0.24; OS 31% versus 49%, P = 0.17) or between
patients with DHL compared with those without DHL (PFS 40%
vs 34%, P = 0.62; OS 50% vs 38%, P = 0.46). In this series of
patients, alloSCT was able to produce durable remissions in
patients with relapsed or refractory aggressive B-NHL, irre-
spective of DEL and DHL status.53
In patients not eligible to high dose chemotherapy plus
transplantation or in patients with refractory disease or
relapsed after autologous transplant, the prognosis is very
poor with standard chemotherapy and novel agents should be
considered.54–57Novel salvage treatments
Targeted therapy
While current prognostic biomarkers, including COO classifica-
tion, have not clearly demonstrated which patients will respond
to targeted therapies, novel genomic classifications have the
potential to improve incorporation of these drugs into personal-
ized treatment strategies.
B-cell receptor inhibitors. Bruton tyrosine kinase (BTK) is a
member of the TEC family of kinases, which has been identified
as a key signaling component downstream of the B-cell receptor
(BCR).58 Abnormalities inBTKwere originally found to drive the
pathogenesis of X-linked agammaglobulinemia (XLA), an
immunodeficiency associated with inhibition of B-cell develop-
ment, and later linked to the B-cell malignancies.59 This finding
led to the development of the first-in-class, oral, covalent BTK
inhibitor, ibrutinib, as well as next generation BTK inhibitors,
such as acalabrutinib. It has been hypothesized that ABC subtype
DLBCLs have increased sensitivity to BTK inhibition given
dependence on constitutive NF-кB signaling, a downstream
effector of BTK, for survival and proliferation.60 Early phase
trials supported preclinical data, with the phase I/II trial of
ibrutinib monotherapy in relapsed/refractory DLBLC resulting in
an ORR of 37% (14/38) in patients with ABC DLBCL, but only
5% (1/20) in patients with GCB DLBCL (P = 0.0106).61
Specifically, among patients with ABC subtype DLBCL,
responses were seen in 3/5 patients with CD79B mutations, 4/
4 patients withCD79B andMYD88mutations, 0/4 patients with
isolated MYD88 mutations, and 0/3 patients with CARD11
mutations.61,62 The median progression-free survival (PFS) in
responding patients was 5.5 months. Despite this encouraging
early-phase data, the randomized trial Phoenix in the frontline
setting have failed to demonstrate a benefit of adding ibrutinib to
chemotherapy in patients with non-GCB DLBCL.13 Several
causes can explain this result: first of all, the COO profile was
assessed by immunohistochemistry based on Hans’ algorithm
and not by gene expression profiling or nanostring technologies;
second, R-CHOP plus placebo treated patients has an impressive
outcome, making the hypothesis of a bias selection in enrolled
patients into the trial; last but not least, elderly experienced more5toxicities compared to young patients, determining premature
discontinuation of the treatment. The exploratory analysis
conducted on patients younger than 60 years, showed a benefit
of adding ibrutinib to R-CHOP in term of EFS, PFS, and OS,
compared to R-CHOP alone. The risk profile for ibrutinib plus R-
CHOP seems to be age dependent, maybe due to multiple factors,
including immune suppressive effects of iBTK. Further studies are
needed to confirm this data. A deeper understanding of the
genomic underpinnings of DLCBL, however, suggest a potential
role of BTK inhibitors in the correct genomic context. Patient
with CD79B MYD88L265Pdouble mutations (MCD) or those
with near-uniform BCL2 copy gain, frequent activating
MYD88L265P and CD79B mutations (cluster 5), for example,
may benefit from the incorporation of targeted BTK inhibition in
their lymphoma treatment.25,26 Additional studies aimed at
utilization of genomic signatures to guide the use of targeted
therapy are required to confirm this possibility.
Additional downstream signaling components of B-cell
receptor signaling include SYK and PYC. While again there
was promising preclinical rationale for the role of SYC and PYC
inhibitors, clinical trials in patients with DLBCL were disap-
pointing. For example, a multicenter phase II study of
fostamatinib, in which 68 patients with DLBCL were enrolled
(58% GCB, 30% ABC, 12% unclassifiable), resulted in an ORR
of only 3%.63 Similarly, inhibition of PKC-b, a downstream
effector of multiple signaling pathways, had limited efficacy as
both a salvage and maintenance therapy.64
Lenalidomide. Lenalidomide is an oral immunomodulatory
drug with direct antineoplastic activity and immunologic effects.
Preclinical data suggests that lenalidomide’s anti-tumor proper-
ties include inhibition of tumor necrosis factor-a, vascular
endothelial growth factor, and NFkB activity.65 In DLBCL, it has
further been shown that anti-tumor effects were associated with
downregulation of interferon regulatory factor 4 (IRF4), a
hallmark of ABC DLBCL cells.66 These findings led to studies in
aggressive non-Hodgkin lymphomas (NHLs), including patients
with DLBCL.67,68 For example, an international, phase II trial of
lenalidomide in 217 patients with relapsed or refractory
aggressive NHL, led to an ORR of 35%.68 In the DLBCL
cohort, the ORRwas 28%with 7% complete response (CR) rate.
Disappointingly, patients with DLBCL had the shortest median
PFS and response duration of 2.7 and 4.6 months, respectively.
Given limited activity of lenalidomide as a single agent, it has also
been studied in combination with rituximab in patients with
relapsed/refractory DLBCL, transformed follicular lymphoma
and grade 3 follicular lymphoma.69 In this study, responses were
slightly improved, with an ORR of 33% and median response
duration of 10.2 months. As with other targeted therapies,
lenalidomide has also been studied in combination with frontline
chemotherapy R-CHOP. Phase II studies suggested that
lenalidomide may mitigate the negative prognosis associated
with non-GCB DLBCLs and true ABC DLBCLs assessed y
GEP.70–72 Unfortunately, preliminary data of the Robust phase
III randomized trial, investigating R-CHOP plus lenalidomide/
placebo in ABC-DLBCL patients, showed no improvement in PFS
by adding lenalidomide in this setting of patients; full analysis is
ongoing.14
Proteasome inhibitors. Proteasome inhibitors, such as borte-
zomib, have also been proposed to increase activity in ABC
DLBCLs. Bortezomib acts by blocking degradation of IkBa,
consequently inhibiting NF-kB activity. Initial studies have
shown limited activity of bortezomib as a single agent in
relapsed/refractory DLBCL. However, when bortezomib was
A. Chiappella et al. Are We Ready to Treat Diffuse Large B-Cell and High-Gradecombined with chemotherapy, a small study demonstrated
increased responses (83% versus 13%) and median OS (10.8
months versus 3.4 months) in ABC as compared to GCB
DLBCL.73 It should be noted that this studywas small with only
12 patients with ABC and 15 patient CGB subtype DLBCL. The
addition of bortezomib in combinationwithR-CHOP for initial
therapy of DLBC also showed a benefit of proteasome
inhibition in high-risk patients.11 Based on these encouraging
preliminary studies, a randomized phase II trial comparing R-
CHOP to R-CHOP plus bortezomib in patients with non-GCB
subtype DLBCLwas performed.12 The results of this studywere
disappointing (from a personalized therapy perspective) with
anORRof 98%and 96%and2-year survival rate of 88.4%and
93.0%, with R-CHOP and R-CHOP plus bortezomib,
respectively.
Anti-apoptotic inhibitors. Anti-apoptotic inhibitors are an
exciting class of therapy with efficacy across a range of
hematologic malignancies. Given frequent BCL-2 over-expres-
sion and the presence of BCL-2 translocations in DLBCL and
high-grade B-cell lymphomas, both correlated with unfavorable
outcome, there has been a particular interest in studying the BCL-
2 inhibitors, such as venetoclax, in these diseases. While
venetoclax was found to be highly active in chronic lymphocytic
leukemia (CLL), with rapid onset of tumor lysis in the phase I
study, results were more modest in DLBCL.74 The phase I study
of venetoclax in patients with NHL enrolled 109 patients, 34 of
whom had DLBCL. In the DLBCL subset, there was an ORR of
18%with a CR rate of 12%, suggesting that while the majority of
patients did not respond, there may be limited subset of patients
with sensitivity to BCL-2 inhibition.75 While the COO, BCL-2
expression, or BCL-2 translocation status of the patients on this
trial were not known, efforts to identify biomarkers of response
are ongoing. For example, the phase II CAVALLI study has
studied the addition of venetoclax to R-CHOP in 208 patients
with DLBCL and with a non-randomized comparison with the
Goya study population, the study demonstrated that this
association may be most beneficial in patients with BCL-2
overexpression or translocation, though randomized trials will be
required to confirm these findings.76 Recent preclinical work has
also identified genomic subtypes that may be most susceptible to
BCL-2 inhibition. Specifically, in vitro and in vivo models
representative of the recently described cluster 3, which consisted
of high-risk GCB DLBCLs with BCL2 SVs, inactivating
mutations and/or copy loss of PTEN and alterations of epigenetic
enzymes, as well as cluster 5, which consist of high-risk ABC
DLBCLs with near-uniform BCL2 copy gain, frequent activating
MYD88L265P and CD79Bmutations, are more sensitive to BCL2
inhibition, especially in combination with PI3Ka/d blockade.77Immunotherapy
In recent years, the advent of CAR-T cells has revolutionized the
treatment of relapsed/refractory DLBCL. Bispecific antibodies,
which provide a theoretically similar mechanism of anti-tumor
activity, are also in active development.
CAR-T cells. Anti-CD19-directed chimeric antigen receptor
(CAR) T-cells are acquiring a role in treatment of DLBCL
relapsed after or refractory to chemotherapy. Since first use in
humans in 2010,78 many efforts have been made to develop new
generations of CAR-T-cells and to better understand possible
clinical applications and toxicities. Today two different products,
axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (t-cel) have
been approved from FDA and EMA for treatment of refractory or6relapsed DLBCL patients after at least two prior lines of systemic
therapy. A third product, the lisocabtagenemaraleucel (liso-cel) is
anticipated to be approved by FDA in 2019. Differently from
other new compounds, this new treatment is not an “off-the-
shelf” drug, indeed the availability of CAR-T-cells is not
immediate. Infact the T-cells are collected from the patients,
then the cell product is genetically modified and then is reinfused
to the patients.
Axi-cel contains a CD28 costimulatory domain in addition to a
CD3 zeta domain. The Phase 2 ZUMA-1 study enrolled 111
patients and 101 of them received axi-cel.79 Overall Response
rate (ORR) was 82% and 54% of patients achieved a CR, among
77 DLBCL patients, CRwas achieved in 49%. CRwas durable at
a median follow-up of 15.4 months in 70% of patients. The
updated follow-up at 2 years for these patients showed that the
median OS is not reached and 39% of patients have ongoing
responses 2 year after the infusion.80 Recent data showed an
ORR of 81% and CR of 57% at 90 days among 274 patients
treated outside clinical studies with the axi-cel commercial
product81 in 17 US centers. Real life toxicity profile was also
similar to the ZUMA-1 study. T-cell contains a 4-1BB
costimulatory domain. Following promising results observed in
a Phase I study, a large multicenter phase II study was conducted,
the JULIET trial.82 Among 106 infused patients the ORR was
50% and CR rate was 32%, in the subgroup of 16 high grade
lymphoma patients the ORRwas 50% indicating that the clinical
response was independent from the genetic lesions. Liso-cel has a
4-1BB costimulatory domain and is engineered so that the final
product has a defined composition of CD4 and CD8 T-cells.
Among 73 evaluable patients, ORR was 80% and CR rate was
59%.83 Administrations of these products is correlated to a
remarkable toxicity. Cytokine Release Syndrome (CRS) and
Neurotoxicity (NT) are fearsome and potentially life-threatening.
Comparison of toxicity incidence and grading between different
products is not easy because of the different toxicity-scale used in
the studies. However, all grade CRS incidence is ranging between
37% and 93% with a percentage of Grade≥3 in 1 to 22% of
patients. The rate of NT of all grades is ranging between 23% and
65% with grade more than 3 in 12 to 31% of patients. Majority
of toxicities resolved in a median of 15 days using immunosup-
pressive drugs like the anti-IL6 receptor antibody (Tocilizumab)
and steroids in case of CRS and corticosteroids alone in case of
neurotoxicity. Today, considering all patients affected by DLBCL
treated with CAR T-cells the rate of mortality related to the
treatment is estimated around 2% to 4%. Infections and
prolonged cytopenias have been also reported.
Based on the data available to date, it appears that the anti-
tumor immune activity of CD19-CAR-T cells is independent of
molecular profile for DLBCL. Indeed, in the ZUMA-1 study, the
ORR in patients with DEL and HGBL was 91%, with a CR rate
of 70%, similar to that in the entire cohort.80 DHL/THL was not
broken out as a subgroup in this analysis. However, in the
JULIET trial, patients with DHL/THL comprised a significant
proportion of the cohort (19/70, 27%), and their ORR was the
same as patients without DHL/THL.82 In addition, the ORR of
patients with GCB DLBCL was also very similar to that of
patients with ABC DLBCL. Comparing to standard population
of R/R DLBCL, patients included into these trials appear to be
younger and with better performance status, suggesting a selected
population, while additional experience is necessary to defini-
tively answer this question, it seems that CD19-CAR-T is a
powerful therapy for all forms of DLBCL, regardless of COO and
more importantly regardless of DHL/DEL status. It is tempting to
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Table 2
More Recent Abstracts on Bispecific Antibodies in DLBCL Treatment
Antibody Antigens Phase
N of
DLBCL pts
ORR in DLBCL
treated at
optimal dose
CR in
DLBCL
Median Duration
of response Ref
Blinatumomab CD19 x CD3 II (Blinatumomab as second salvage in R/R) 41 37% 22% PFS 51% at 9 months 86
Mosunetuzumab CD20 x CD3 I/Ib 55 13/39 8/39 372 days 87
RG6026 CD20 x CD3 (2:1) I 64 13/24 5/24 NA 88
(2019) 3:5 www.hemaspherejournal.comspeculate that this remarkable feature of CAR-T treatment could
apply more broadly to immunotherapy, making this potentially a
cornerstone of future treatment of these high-risk DLBCL
variants.
Bispecific antibodies. Bispecific T-cell engagers (BiTEs) anti-
bodies consist of 2 single-chain variable fragments specific for
CD3 and a tumor antigen; when the antibody binds to the
antigen, cytotoxic T-cells are directed against the tumor cell
resulting in cell lysis. Considering the characteristic expression of
specific antigen such as CD19 and CD20 in B-cell malignancies,
they are a natural target for the development of this type of
immunotherapy. Differently from the adoptive T-cells immuno-
therapy with CAR T-cells, BiTEs are an off-the-shelf drug
available without need of patient-dedicated manufacturing. The
development of bispecific antibodies is exploring a broad range of
tumor antigens as targets for new antibodies with potential
applications in myeloma, leukemia and lymphoma patients.
Blinatumomab was the first-in-class CD19-specific BiTE
approved by FDA in 2014 for the treatment of patients with
relapsed or refractory acute lymphoblastic leukemia. Considering
the expression of CD19 by lymphoproliferative diseases derived
from the B lineage, efficacy of this drug in DLBCL patients has
been tested. In 2016 a phase I study showed an ORR of 69%
among 76 relapsed and refractory lymphoma patients treated
with Blinatumumab at escalating dose. DLBCL patients were 14
with an ORR of 55% and a median duration of response of 13.5
months.84 A similar response rate of 43% with 19% of complete
response was observed among 21 DLBCL patients treated in a
Phase II study.85 Many others new bispecific antibodies directed
against CD19 and CD20 are under evaluation in clinical trials
involving patients with different lymphoma hystologies. Prelimi-
nary results show promising results also in patients with
refractory and relapsed aggressive lymphomas with durablePathologic Analysis: DLBCL 
Genomic Analys
WES and use of tar
NGS panels  
Biopsy and/or 
collection of cfDNA 
Figure 1. Potential role of genomic profiling to g
7response in patients achieving complete remissions (Table 2).
Common adverse events reported during treatment with
bispecific antibodies are the cytokine release syndrome and the
neurological toxicities. Many patients present fever and chills,
more severe reactions with hypotension and multiorgan failure
due to the macrophage activation are less frequent and are
reported only during the first cycle. Neurological adverse events
have been reported in 50% of patients with symptoms ranging
from tremors to seizures or encephalopathy.
To date, there is very little information on the response of
specific DLBCL subgroups, in particular DHL/THL or DEL, to
bispecific antibodies. The results of CAR-T cells lend hope that
bispecifics could also be equally efficacious in those subgroups,
but such speculation awaits confirmation from larger studies.Conclusions and future approaches
In recent years, there has been a dramatic expansion in our
knowledge regarding the biology and heterogeneity of DLBCL, as
well as an expansion of available therapeutic options, with new
availability of both immune-based and targeted treatments.
However, despite significant progress, particularly with the
advent of CART cell therapy, there remains a subset of patients
who are less likely to achieve durable response with frontline
therapy, and still today only a minority of patients with relapsed
or refractory disease will achieve a cure. While providing a useful
starting point for categorization, the COO classification has to
date not allowed the optimization of front-line or curative-intent
salvage therapy, and no specific therapy has been developed for
DHL/THL or DEL. Recent genomic analyses have shed more
light on the genomic complexity of DLCB and promise a better
possibility of personalized therapy (Fig. 1). In addition, such
work may refine our biological understanding of MYC-is: 
geted 
 
Cluster 1 
Cluster 2 
Cluster 3 
Cluster 4
Cluster 5 
Genomic Cluster Designation
Personalized Therapy 
uide precision medicine strategies in DLBCL.
15. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with
A. Chiappella et al. Are We Ready to Treat Diffuse Large B-Cell and High-Gradederegulated DLBCL, which may betray an additional layer of
biological complexity that interacts with the broader genomic
profile. This could allow rational combinations to be tested in
precisely defined subsets. It may be hoped that this body of work
will fuel efforts focused on validating and refining genomic
classification structures, biomarkers of response, and developing
effective targeted therapies, that could be used in combination
with chemotherapy, with each other, or with the powerful new
tools of immunotherapy.
To this end, it will also be necessary to develop broadly
available and affordable sequencing tools. Furthermore, given the
aggressive nature of DLBCL, genomic information and classifi-
cation must be available in a short time frame in order to be
clinically relevant. Further improvements in sequencing plat-
forms, the development of targeted sequencing panels, and use of
cell free DNA (cfDNA), which could abrogate the need for tumor
biopsies, have the potential to improve the process of genomic
classification and utility of these technologies to improve care for
patients with DLBCL.89
Ultimately, such broad and multifaceted efforts are likely
required if we aim to cure all patients with DLBCL.References
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